非小细胞肺癌中肿瘤细胞程序性死亡配体1表达与免疫细胞浸润的预后影响
在705例未接受PD-1/PD-L1抑制剂治疗的回顾性手术NSCLC队列中,CD8和IGKC阳性免疫细胞浸润较高与总生存期较长相关(分别p=0.004和p<0.001)。PD-L1阳性在非分层人群中与OS无关联,但在从不吸烟者中与较短OS显著相关(5%和50%截断值下p=0.009和p=0.002)。PD-L1阳性肿瘤(50%截断值)中淋巴细胞浸润与OS无关。
要点
- CD8和IGKC阳性细胞浸润较高与NSCLC患者更长OS相关(p=0.004和p<0.001)。
- PD-L1阳性在从不吸烟者中与较短OS显著相关(5%和50%截断值下p=0.009和p=0.002)。
- PD-L1阳性肿瘤(50%截断值)中淋巴细胞浸润与OS无关。
核心结论
- 若将淋巴细胞浸润用作预后生物标志物,应考虑增殖、PD-L1状态、吸烟史和组织学类型。
研究设计与样本
- 两个回顾性手术NSCLC患者队列,患者未接受靶向PD-1/PD-L1轴的检查点抑制剂治疗。
- 通过组织微阵列(n=705)免疫组化检测CD3、CD8、CD4、FOXP3、CD20、CD79A和IGKC阳性免疫细胞及肿瘤PD-L1阳性。
- 对患者子集分析Affymetrix数据,并补充公开转录组数据(N=1724)。
- 通过Kaplan-Meier图和单因素及多因素Cox回归评估与OS的关联。
主要发现
- CD8和IGKC阳性细胞水平较高分别与更长OS相关(p=0.004和p<0.001)。
- 高增殖且淋巴细胞少的肿瘤预后最差。
- 非分层患者人群中未观察到PD-L1阳性与OS的关联。
- 从不吸烟者中PD-L1阳性与较短OS显著相关(5%和50%截断值下p=0.009和p=0.002)。
- PD-L1阳性肿瘤(50%截断值)中淋巴细胞浸润与OS无关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Infiltration of T and B/plasma cells has been linked to NSCLC prognosis, but this has not been thoroughly investigated in relation to the expression of programmed death ligand 1 (PD-L1). Here, we determine the association of lymphocytes and PD-L1 with overall survival (OS) in two retrospective cohorts of operated NSCLC patients who were not treated with checkpoint inhibitors targeting the programmed death 1/PD-L1 axis. Moreover, we evaluate how PD-L1 positivity and clinicopathologic factors affect the prognostic association of lymphocytes. METHODS: Cluster of differentiation (CD) 3 (CD3)-, CD8-, CD4-, forkhead box P3 (FOXP3)-, CD20-, CD79A-, and immunoglobulin kappa constant (IGKC)-positive immune cells, and tumor PD-L1 positivity, were determined by immunohistochemistry on tissue microarrays (n = 705). Affymetrix data was analyzed for a patient subset, and supplemented with publicly available transcriptomics data (N = 1724). Associations with OS were assessed by Kaplan-Meier plots and uni- and multivariate Cox regression. RESULTS: Higher levels of T and B plasma cells were associated with longer OS (p = 0.004 and p < 0.001, for CD8 and IGKC, respectively). Highly proliferative tumors with few lymphocytes had the worst outcome. No association of PD-L1 positivity with OS was observed in a nonstratified patient population; however, a significant association with shorter OS was observed in never-smokers (p = 0.009 and p = 0.002, 5% and 50% cutoff). Lymphocyte infiltration was not associated with OS in PD-L1-positive tumors (50% cutoff). The prognostic association of lymphocyte infiltration also depended on the patients' smoking history and histologic subtype. CONCLUSIONS: Proliferation, PD-L1 status, smoking history, and histology should be considered if lymphocyte infiltration is to be used as a prognostic biomarker.
引用
- Edlund K, Madjar K, Mattsson JSM, et al. Prognostic Impact of Tumor Cell Programmed Death Ligand 1 Expression and Immune Cell Infiltration in NSCLC. J Thorac Oncol. 2019. PMID: 30639618. doi:10.1016/j.jtho.2018.12.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。